Clinical trials: MG
Myasthenia Gravis (MG)
The Effectiveness of an ETP Programme in Myasthenia Gravis: a Proof-of-concept Study.
CONTEXTE. Myasthenia gravis is a rare neuromuscular junction disorder affecting one in five thousand people (ORPHA 589). It is a chronic condition that progresses in episodes.
- Trial name
- MY-EDUC (NCT07512375)
- Testing
- CBSM
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
ESPB, Mg Sulfate,Post Mastectomy
Efficacy of Magnesium Sulfate as an Adjuvant in Erector Spinae Plane Block as an Anesthetic Post Operative After Modified Radical Mastectomy
efficacy of magnesium sulfate as an adjuvant in erector spinae plane block as an anesthetic post-operative after modified radical mastectomy
- Trial name
- NCT05976464
- Testing
- Magnesium sulfate in erector spinae plane block
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Myasthenia Gravis (MG)
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
Through a retrospective cohort study method, the influence of Gu-Lu Er-Xian Decoction with modified formula on the long-term therapeutic effect of patients with myasthenia gravis was analyzed, and the related factors affecting…
- Trial name
- NCT07472777
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Beijing University of Chinese Medicine
System Lupus Erythematosus(SLE), Scleroderma
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the…
- Conditions
- System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG)
- Trial name
- NCT07470151
- Testing
- EVM18001 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SLE, Sclerosis
A Study of RD06-04 in Patients With Active Autoimmune Diseases
This is an open-label, Phase I, investigator-initiated trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with autoimmune diseases mediated by…
- Conditions
- SLE, Sclerosis, ANCA Associated Vasculitis, IIM
- Trial name
- NCT06548620
- Testing
- RD06-04 cell infusion
- Where
- China
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
SLE, Systemic Sclerosis
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS…
- Conditions
- SLE, Systemic Sclerosis, IIM, NMOSD
- Trial name
- NCT06775912
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Myasthenia Gravis (MG)
Ripertamab for the Treatment of Myasthenia Gravis
The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab.
- Trial name
- RIPERT-MG (NCT07372807)
- Testing
- ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu
Higher Uric Acid Concentrations (>5,5 mg/dl), Healthy
Influence of Hesperidin and Vitamin C on Uric Acid Concentration
Aim of the study is to investigate the impact of hesperidin and/or vitamin C on elevated uric acid concentrations.
- Trial name
- HesperiDrinC (NCT04316390)
- Testing
- Control, Hesperidin, Vitamin C
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Kiel
Fever, Leukocytes
Link Between Eosinopenia and Bacterial Infections in the Elderly Subject Hospitalized in Geriatrics
The main purpose of this monocentric, non-interventional, prospective study carried out in acute geriatrics (UGA) and post-rehabilitation care, is to determine if eosinopenia is associated with bacterial infections.
- Conditions
- Fever, Leukocytes, C Reactive Protein (CRP) is Less Than 20 mg/ l
- Trial name
- ELISA (NCT04363138)
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Gérond'if
Gout, CKD Stage 1-4
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by eGFR and albuminuria (A) [2].
- Conditions
- Gout, CKD Stage 1-4, SUA Level (>8 mg/dL; 480 µmol/L)
- Trial name
- IMPULsKF (NCT03336203)
- Testing
- Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
- Where
- Ukraine
- Volunteers
- 2 people
- Sponsor
- Medical Practice Prof D. Ivanov
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
- Trial name
- NCT02937766
- Testing
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone
High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19
In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic…
- Trial name
- NCT05047874
- Testing
- systemic methylprednisolone
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Biruni University
1mg Vs 3 mg of Granisetron
A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA
Investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic surgeries under general anesthesia to prevent postoperative nausea and vomiting
- Trial name
- NCT04918862
- Testing
- Granisetron
- Where
- Egypt
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cairo University
Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)
Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
The proposed study is a sub-study of the CANTOS trial (A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable…
- Conditions
- Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
- Trial name
- NCT01900600
- Testing
- Cardiopulmonary exercise test, Echocardiogram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Virginia Commonwealth University
Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed, Placebo
Pexacerfont for Stress-induced Food Craving
Background: Stress can cause people to give in to temptations to eat less healthily. People who are on weight loss diets often have problems sticking to their diets when they are stressed.
- Trial name
- NCT01656577
- Testing
- Pexacerfont
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Diabetic Patients, Low HDL-cholesterol (< 35 mg/dL)
DLBS1449 in Diabetic Patients With Low HDL
This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449 in elevating high density lipoprotein (HDL)…
- Conditions
- Diabetic Patients, Low HDL-cholesterol (< 35 mg/dL), Lifestyle Intervention for at Least 1 Month
- Trial name
- NCT01972477
- Testing
- DLBS1449
- Where
- Indonesia
- Sponsor
- Dexa Medica Group
To Demonstrate That the Closed Loop System Can be Used Safely Over a Few Consecutive Days., To Assess Effectiveness in Maintaining Patients' Glucose Levels in the Target Range of 70 to 180 mg/dl, Measured by Blood Glucose Sensor.
Multiday Fully Closed Loop Insulin Delivery in Monitored Outpatient Conditions
Insulin replacement therapy is absolutely required for patients with Type 1 diabetes. The insulin pump provides for continuous subcutaneous insulin infusion (CSII), which can approximate the insulin release patterns of the normal…
- Conditions
- To Demonstrate That the Closed Loop System Can be Used Safely Over a Few Consecutive Days., To Assess Effectiveness in Maintaining Patients' Glucose Levels in the Target Range of 70 to 180 mg/dl, Measured by Blood Glucose Sensor., To Evaluate the User Experience With a Closed Loop System
- Trial name
- NCT02127827
- Testing
- Automated Ambulatory Glycemic Controller (AAGC)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Comparison of Two Formulations of Proellex for Vaginal Administration
This study is a double-blind crossover study in female healthy volunteers to compare the pharmacokinetics and safety of either 1 or 6 days of dosing with two different formulations of Proellex for vaginal administration.
- Trial name
- NCT01962805
- Testing
- Proellex Formulation A, Proellex Formulation B
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic metabolic disorder which is caused by both insulin secretion deficiency and insulin action defect.
- Conditions
- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in, Subjects With Type 2 Diabetes Mellitus.
- Trial name
- NCT01245166
- Testing
- Acarbose, Metformin/Acarbose
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- Lotus Pharmaceutical